Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)

Dr. Carl Pepine

Cardiology
Uf Health Sports And Exercise Cardiology-Springhill
4037 NW 86th Ter Fl 2, 
Gainesville, FL 
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Uf Health Sports And Exercise Cardiology-Springhill
4037 NW 86th Ter Fl 2, 
Gainesville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Carl Pepine is a Cardiologist in Gainesville, Florida. Dr. Pepine is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Angina, Coronary Heart Disease, Hypertension, Bone Marrow Aspiration, and Percutaneous Coronary Intervention (PCI).

His clinical research consists of co-authoring 467 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 24 articles and participated in 1 clinical trial in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Specialties
Cardiology
Licenses
Internal Medicine in FL
Hospital Affiliations
Uf Health Shands Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

Uf Health Sports And Exercise Cardiology-Springhill
4037 NW 86th Ter Fl 2, Gainesville, FL 32606

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug, Behavioral
Study Drugs: Statin, Lisinopril, Losartan, Aspirin
Study Phase: Phase 4
Gut Inflammation and Gut-Gut Microbiome Interactions in the Pathogenesis of Hypertension
Gut Inflammation and Gut-Gut Microbiome Interactions in the Pathogenesis of Hypertension
Enrollment Status: Completed
Publish Date: September 29, 2025
Intervention Type: Other
Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients With Ischemic Heart Failure (CardiAMP Heart Failure Trial)
Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients With Ischemic Heart Failure (CardiAMP Heart Failure Trial)
Enrollment Status: Completed
Publish Date: September 19, 2025
Intervention Type: Other, Biological
Study Drug: Autologous Cell Therapy
Study Phase: Phase 3
The Role of Gut Microbiota in Hypertension: Brain-Gut Microbiome-Immune Axis in Hypertension
The Role of Gut Microbiota in Hypertension: Brain-Gut Microbiome-Immune Axis in Hypertension
Enrollment Status: Completed
Publish Date: August 17, 2025
Intervention Type: Other
Characterize the Gut Microbiota in Subjects With Heart Failure and Pre-heart Failure With Preserved Ejection Fraction
Characterize the Gut Microbiota in Subjects With Heart Failure and Pre-heart Failure With Preserved Ejection Fraction
Enrollment Status: Withdrawn
Publish Date: April 10, 2025
Intervention Type: Other
Phase 1 Study of Mesenchymal Stromal Cells, Umbilical Cord Lining Stem Cells (ULSC), in Patients With Polymyositis (PM) and Dermatomyositis (DM)
Phase 1 Study of Mesenchymal Stromal Cells, Umbilical Cord Lining Stem Cells (ULSC), in Patients With Polymyositis (PM) and Dermatomyositis (DM)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Umbilical Cord Lining Stem Cells
Study Phase: Early Phase 1
Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With a Myocardial Infarction and Ischemic Left Ventricular Dysfunction
Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With a Myocardial Infarction and Ischemic Left Ventricular Dysfunction
Enrollment Status: Terminated
Publish Date: April 09, 2024
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Enrollment Status: Completed
Publish Date: January 10, 2022
Intervention Type: Biological, Other
Study Phase: Phase 3
A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, & Efficacy of Autologous Mesenchymal Stem Cells & C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF
A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, & Efficacy of Autologous Mesenchymal Stem Cells & C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF
Enrollment Status: Completed
Publish Date: April 26, 2021
Intervention Type: Biological
Study Phase: Phase 2
A Phase I, First-in-Human, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors With Anthracycline-Induced Cardiomyopathy
A Phase I, First-in-Human, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors With Anthracycline-Induced Cardiomyopathy
Enrollment Status: Completed
Publish Date: November 05, 2020
Intervention Type: Biological
Study Phase: Phase 1
View 9 Less Clinical Trials

468 Total Publications

The Gut Microbiome and Cardiac Arrhythmias.
The Gut Microbiome and Cardiac Arrhythmias.
Journal: Federal practitioner : for the health care professionals of the VA, DoD, and PHS
Published: October 06, 2025
Similar Doctors
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Sumant Lamba
Cardiology
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Sumant Lamba
Cardiology

First Coast Cardiovascular Institute - Mandarin Office

9759 San Jose Blvd Ste 2, 
Jacksonville, FL 
 (58.0 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sumant Lamba is a Cardiologist in Jacksonville, Florida. Dr. Lamba is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Heart Failure, Heart Failure with Preserved Ejection Fraction (HFpEF), Pediatric Myocarditis, Necrosis, and Atherectomy.

Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Jonathan Constantin
Cardiology
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Jonathan Constantin
Cardiology

AdventHealth Medical Group Heart Care At Pine Avenue

1219 S Pine Ave Ste 204, 
Ocala, FL 
 (35.0 miles away)
352-354-9000
Languages Spoken:
English
See accepted insurances

Jonathan Constantin is a Cardiologist in Ocala, Florida. Dr. Constantin is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Pediatric Myocarditis, Necrosis, Angina, and Heart Failure.

Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Suman Pasupuleti
Cardiology
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Suman Pasupuleti
Cardiology

Citrus Cardiology Consultants PA

308 W Highland Blvd, 
Inverness,, FL 
 (55.3 miles away)
Languages Spoken:
English
See accepted insurances

Suman Pasupuleti is a Cardiologist in Inverness,, Florida. Dr. Pasupuleti is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Mitral Valve Regurgitation, Angina, Necrosis, Pacemaker Implantation, and Cardiac Ablation.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pepine's expertise for a condition
ConditionClose
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile